0,05. Доказательная медицина от магии до поисков бессмертия

Echt D. S., Liebson P. R., Mitchell L. B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Supression Trial // The New England journal of medicine. 1991. March 21. Vol. 324. № 12. P. 781–788.

Moore T. J. Deadly Medicine: Why tens of thousands of heart patients died in america’s worst drug disaster. New York: Simon and Schuster, 1995.

Teo K. K., Yusuf S., Furberg C. D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized trials // JAMA. 1993. October 6. Vol. 270. № 13. P. 1589–1595.

Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? // Lancet. 1995. June 10, Vol. 345. № 8963. P. 1455–1463.

Morgan D. J., Brownlee S., Leppin A. L., Kressin N., Dhruva S. S., Levin L. et al. Setting a research agenda for medical overuse // BMJ. 2015. August 25. Vol. 351. № 1, h4534.

Spencer I. Lessons from history: the politics of psychiatry in the USSR // Journal of Psychiatric and Mental Health Nursing. 2000. August. Vol. 7. № 4. P. 355–361.

Bloch S. Psychiatry as ideology in the USSR // Journal of medical ethics. 1978. Vol. 4. P. I26–13I.

Cochrane A. L., St Leger A. S., Moore F. Health service ‘input’ and mortality ‘output’ in developed countries // Journal of epidemiology and community health. 1978. September. Vol. 32. № 3. P. 200–205.

Carr-Hill R. A., Hardman G. F., Russell I. T. Variations in avoidable mortality and variations in health care resources // Lancet. 1987. April 4. Vol. 1. № 8536. P. 789–792.

Metcalfe D., Chowdhury R., Salim A. What are the consequences when doctors strike? // BMJ. 2015. November 25. Vol. 351. № 8035, h6231.

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. January 10. Vol. 385. № 9963. P. 117–171.

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. August 22. Vol. 386. № 9995. P. 743–800.

Kelly W. N. Can the frequency and risks of fatal adverse drug events be determined? // Pharmacotherapy. 2001. May. Vol. 21. № 5. P. 521–527.

Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analyses of prospective studies // JAMA. 1998. April 15. Vol. 279. № 15. P. 1200–1205.

Starfield B. Is US health really the best in the world? // JAMA. 2000. July 26. Vol. 284. № 4. P. 483–485.

Phillips D. P., Christenfeld N., Glynn L. M. Increase in US medication-error deaths between 1983 and 1993 // Lancet. 1998. February 28. Vol. 351. № 9103. P. 643–644.

Klevens R. M., Edwards J. R., Richards C. L., Horan T. C., Gaynes et al Estimating healthcare-associated infections and deaths in U. S. hospitals, 2002 // Public Health Reports. 2007. March-April. Vol. 122. № 2. P. 160–166.

Ernst F. R., Grizzle A. J. Drug-related morbidity and mortality: updating the cost-of-illness model // Journal of the American Pharmaceutical Association. 2001. March/April. Vol. 41. № 2. P. 192–199.

Johnson J. A., Boatman L. Drug-related morbidity and mortality: A Cost-of-illness model // Journal of Managed Care Pharmacy. 1996. January/February. Vol. 2. № 1. P. 39–47.